

Joe O'Sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/956621/publications.pdf>

Version: 2024-02-01

134
papers

10,687
citations

87888

38
h-index

31849

101
g-index

139
all docs

139
docs citations

139
times ranked

9873
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
2	Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy. <i>Nuclear Medicine and Biology</i> , 2022, 106-107, 10-20.	0.6	5
3	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
4	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4
5	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
6	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
7	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
8	Management of newly diagnosed metastatic hormone-sensitive prostate cancer: A survey of UK Urooncologists. <i>International Journal of Clinical Practice</i> , 2021, 75, e13874.	1.7	0
9	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1055-1062.	3.9	4
10	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4549-4556.	7.0	5
11	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Åyr in the CHHiP trial (CRUK/06/016). <i>European Urology Oncology</i> , 2021, 4, 980-992.	5.4	14
12	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 3022-3033.	1.6	24
13	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	5.4	17
14	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. <i>Epidemiology</i> , 2020, 31, 432-440.	2.7	22
15	Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa062.	3.2	0
16	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
17	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer – A UK perspective. <i>International Journal of Clinical Practice</i> , 2020, 74, e13611.	1.7	0
18	A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20200775.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020, 2, zcaa012.	3.1	8
20	Targeted Alpha Therapy: Current Clinical Applications. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 404-417.	1.0	48
21	Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression. <i>British Journal of Cancer</i> , 2020, 122, 1315-1323.	6.4	15
22	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
23	Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 325-325.	1.6	4
24	Results of the ADRRAD Trial of pelvic IMRT plus radium-223 in men with mHSPC metastatic to bone.. <i>Journal of Clinical Oncology</i> , 2020, 38, 136-136.	1.6	0
25	Advances in targeted alpha therapy for prostate cancer. <i>Annals of Oncology</i> , 2019, 30, 1728-1739.	1.2	43
26	Use of Bone Health Agents (BHAs) in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Radium-223 after Abiraterone: An Interim Review of Reassure. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S39-S40.	0.3	0
27	Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 448-456.	0.8	41
28	Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: A 9-month longitudinal study. <i>Psycho-Oncology</i> , 2019, 28, 1743-1752.	2.3	17
29	Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). <i>Pilot and Feasibility Studies</i> , 2019, 5, 102.	1.2	8
30	EP-2032 Automated Bone Scan Index (aBSI) as an Imaging Biomarker in Castration Sensitive Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S1115-S1116.	0.6	0
31	EP-2207 PROMs: Transperineal insertion of prostate markers – results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2019, 133, S1216-S1217.	0.6	0
32	OC-0407 CT-based Radiomics for Risk Stratification in Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S209.	0.6	0
33	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. <i>Annals of Oncology</i> , 2019, 30, 1992-2003.	1.2	262
34	Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S31-S33.	0.3	1
35	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	2.6	36
36	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 348-355.e5.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Radium-223 (Ra-223) Therapy after Abiraterone: Analysis of Symptomatic Skeletal Events (SSEs) in an International Early Access Program (IEAP) in Patients with Metastatic castration-Resistant Prostate Cancer (mCRPC). <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S40.	0.3	0
38	Mechanistic Modeling of Radium-223 Treatment of Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1221-1230.	0.8	8
39	Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 9, 35-40.	1.9	5
40	The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, e51-e52.	1.9	21
41	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	1.9	41
42	Plasma citrulline levels as a biomarker for bowel toxicity in prostate stereotactic radiotherapy with or without pelvic nodal radiation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 73-73.	1.6	0
43	Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel.. <i>Journal of Clinical Oncology</i> , 2019, 37, 196-196.	1.6	0
44	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	1.2	196
45	The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1179-1189.	0.8	33
46	(ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis. <i>Acta Oncologica</i> , 2018, 57, 965-972.	1.8	26
47	Reply to "Single high dose versus repeated bone-targeted radionuclide therapy". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 515-517.	6.4	0
48	Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. <i>British Journal of Radiology</i> , 2018, 91, 20170795.	2.2	9
49	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018, 73, 427-435.	1.9	84
50	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. <i>Annals of Oncology</i> , 2018, 29, 215-222.	1.2	86
51	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e411-e419.	1.9	36
52	Efficacy of a rectal spacer with prostate SABR"first UK experience. <i>British Journal of Radiology</i> , 2018, 91, 20170672.	2.2	11
53	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
54	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90

#	ARTICLE	IF	CITATIONS
55	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	13.7	901
56	TRUFU: Therapeutic radiographer undertaking follow up for prostate cancer patients. <i>Radiography</i> , 2018, 24, 298-303.	2.1	4
57	Semi-permanent tattoos in breast radiotherapy (STaBRad) study: a randomised-controlled clinical trial comparing the "Precision Plus Micropigmentation System"™ to permanent skin tattoos in radical breast radiotherapy patients. <i>Journal of Radiotherapy in Practice</i> , 2018, 17, 12-19.	0.5	3
58	CASPIR trial: Using prostatic calculi as an alternative to fiducial markers for IGRT in for localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 60-60.	1.6	1
59	Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis. , 2018, , .		0
60	Costa Effectiveness of zoledronic acid and strontium ⁸⁹ as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate refractory prostate cancer: results from the <sc>TRAPEZE</sc> trial (<sc>ISRCTN</sc> 12808747). <i>BJU International</i> , 2017, 119, 522-529.	2.5	18
61	Opportunities for research in molecular radiotherapy. <i>British Journal of Radiology</i> , 2017, 90, 20160921.	2.2	4
62	An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. <i>Annals of Oncology</i> , 2017, 28, 1090-1097.	1.2	134
63	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327.	6.4	15
64	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
65	Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. <i>Radiation Oncology</i> , 2017, 12, 53.	2.7	6
66	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017, 104, 150-159.	1.0	29
67	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. <i>Physics in Medicine and Biology</i> , 2017, 62, 2859-2870.	3.0	6
68	Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. <i>European Journal of Cancer</i> , 2017, 71, 1-6.	2.8	45
69	MP57-10 RELATIONSHIP BETWEEN QUALITY OF LIFE AND OVERALL SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN ALSYMPCA: ANALYSIS BY PRIOR DOCETAXEL SUBGROUP. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
70	EP-1841: CASPIR Trial: Interim analysis of prostatic calculi as an alternative to fiducial markers for IGRT. <i>Radiotherapy and Oncology</i> , 2017, 123, S1007.	0.6	0
71	EP-1340: Comparing dosimetry and toxicity of 5-field IMRT versus VMAT for prostate & pelvic nodal irradiation. <i>Radiotherapy and Oncology</i> , 2017, 123, S718-S719.	0.6	0
72	Active surveillance for favorable risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. <i>Psycho-Oncology</i> , 2017, 26, 1411-1421.	2.3	23

#	ARTICLE	IF	CITATIONS
73	Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 620-629.	6.4	18
74	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 42-52.e8.	1.9	75
75	Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). <i>Annals of Oncology</i> , 2017, 28, v620.	1.2	6
76	A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. <i>Radiation Oncology</i> , 2017, 12, 124.	2.7	9
77	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	1.6	54
78	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA5003-LBA5003.	1.6	2
79	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA5003-LBA5003.	1.6	6
80	A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11-11.	1.6	1
81	Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (IEAP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 158-158.	1.6	2
82	A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.. <i>Journal of Clinical Oncology</i> , 2017, 11-11.	1.6	0
83	Relationship between quality of life and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients in ALSYMPCA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 177-177.	1.6	0
84	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. <i>Trials</i> , 2016, 17, 560.	1.6	14
85	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. <i>European Urology</i> , 2016, 70, 875-883.	1.9	67
86	An exploration of men's experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol. <i>BMC Cancer</i> , 2016, 16, 586.	2.6	4
87	SPORT high-risk trial: A randomised feasibility study evaluating stereotactic prostate radiotherapy in high-risk localised prostate cancer with or without elective nodal irradiation. <i>European Journal of Surgical Oncology</i> , 2016, 42, S235.	1.0	1
88	Fiducial marker guided prostate radiotherapy: a review. <i>British Journal of Radiology</i> , 2016, 89, 20160296.	2.2	68
89	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	10.7	259
90	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. <i>Cancer</i> , 2016, 122, 664-673.	4.1	5

#	ARTICLE	IF	CITATIONS
91	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2016, 17, 1047-1060.	10.7	941
92	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	7.1	78
93	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1163-1177.	13.7	1,570
94	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	7.1	155
95	Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10124-10124.	1.6	2
96	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5082-5082.	1.6	20
97	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	2.8	29
98	Does the choice of hormone therapy affect medium-term outcomes following radical external beam radiotherapy for localized prostate cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 97-97.	1.6	0
99	Impact of pre-treatment neutrophil-lymphocyte ratio on outcomes in men receiving radical external beam radiotherapy for localised prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-151.	1.6	0
100	Single institution, retrospective comparison of toxicity and outcome for static 5-field IMRT versus VMAT in the delivery of prostate and pelvic nodal irradiation in high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 147-147.	1.6	0
101	Impact of pre-treatment neutrophil-lymphocyte ratio on outcomes in men receiving radical external beam radiotherapy for localised prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16604-e16604.	1.6	0
102	Does the choice of hormone therapy affect medium-term outcomes following radical external beam radiotherapy for localized prostate cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, e16588-e16588.	1.6	0
103	Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields. <i>International Journal of Radiation Biology</i> , 2015, 91, 257-261.	1.8	5
104	A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Cancer Survivorship</i> , 2015, 9, 431-440.	2.9	53
105	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2015, 16, 1605-1616.	10.7	126
106	Time and Cell Type Dependency of Survival Responses in Co-cultured Tumor and Fibroblast Cells after Exposure to Modulated Radiation Fields. <i>Radiation Research</i> , 2015, 183, 656-664.	1.5	10
107	Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5001-5001.	1.6	72
108	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16108-e16108.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-141.	1.6	23
110	External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 182-182.	1.6	13
111	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. <i>PLoS ONE</i> , 2015, 10, e0118187.	2.5	17
112	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746.	10.7	433
113	Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. <i>Cancer Causes and Control</i> , 2014, 25, 33-43.	1.8	25
114	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology</i> , The, 2014, 15, 1397-1406.	10.7	351
115	Beta-blocker usage and prostate cancer survival: A nested case-control study in the UK Clinical Practice Research Datalink cohort. <i>Cancer Epidemiology</i> , 2014, 38, 279-285.	1.9	38
116	Bicalutamide (150 mg) monotherapy versus LHRHa as neoadjuvant treatment in intermediate- and high-risk prostate cancer: A case matched study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 226-226.	1.6	0
117	From trial to practice: The Northern Ireland cancer center experience with abiraterone acetate in men with metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16101-e16101.	1.6	0
118	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2013, 63, 189-197.	1.9	154
119	What is the Role of the Bystander Response in Radionuclide Therapies?. <i>Frontiers in Oncology</i> , 2013, 3, 215.	2.8	51
120	Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5068-5068.	1.6	4
121	A Kinetic-Based Model of Radiation-Induced Intercellular Signalling. <i>PLoS ONE</i> , 2013, 8, e54526.	2.5	55
122	Sensitivity of PTEN-deficient prostate carcinoma cells to ionizing radiation through inhibition of treatment-induced CXCL8 signaling.. <i>Journal of Clinical Oncology</i> , 2013, 31, 154-154.	1.6	0
123	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 549-558.	10.7	100
124	DNA Damage Responses following Exposure to Modulated Radiation Fields. <i>PLoS ONE</i> , 2012, 7, e43326.	2.5	44
125	Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4551-4551.	1.6	7
126	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4512-LBA4512.	1.6	34

#	ARTICLE	IF	CITATIONS
127	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. Journal of Clinical Oncology, 2012, 30, LBA4512-LBA4512.	1.6	30
128	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology, 2012, 30, 8-8.	1.6	55
129	Neoadjuvant hormone therapy for radical prostate radiotherapy: A case-matched study comparing bicalutamide to LHRH agonist therapy.. Journal of Clinical Oncology, 2012, 30, 88-88.	1.6	0
130	A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1990-1998.	6.4	29
131	The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. Journal of Cancer Survivorship, 2010, 4, 128-139.	2.9	126
132	A study of the biological effects of modulated 6 MV radiation fields. Physics in Medicine and Biology, 2010, 55, 1607-1618.	3.0	29
133	Radiation-induced bystander signalling in cancer therapy. Nature Reviews Cancer, 2009, 9, 351-360.	28.4	703
134	Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- κ B Transcription and Evasion of Apoptosis. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 746-759.	2.5	100